File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Switching to lamivudine in entecavir-treated patients with undetectable HBV DNA - final results at 96 weeks

TitleSwitching to lamivudine in entecavir-treated patients with undetectable HBV DNA - final results at 96 weeks
Authors
Fung, JLai, CLWong, DSeto, WKYuen, MF
KeywordsMedical sciences
Gastroenterology
Issue Date2010
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462 How to Cite?
DOI: http://dx.doi.org/10.1002/hep.23990
AbstractBACKGROUND: The aim of this study was to determine the efficacy of entecavir followed by lamivudine in patients with undetectable viral load and normal ALT after initial entecavir treatment. METHODS: This is a 2-year prospective trial of 50 patients treated on entecavir 0.5 mg daily for over 6 months, and had …
Persistent Identifierhttp://hdl.handle.net/10722/137775
ISSN
0270-9139
2023 Impact Factor: 12.9
2023 SCImago Journal Rankings: 5.011

 

DC FieldValueLanguage
dc.contributor.authorFung, Jen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorWong, Den_US
dc.contributor.authorSeto, WKen_US
dc.contributor.authorYuen, MFen_US
dc.date.accessioned2011-08-26T14:33:10Z-
dc.date.available2011-08-26T14:33:10Z-
dc.date.issued2010en_US
dc.identifier.citationThe 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462en_US
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/137775-
dc.description.abstractBACKGROUND: The aim of this study was to determine the efficacy of entecavir followed by lamivudine in patients with undetectable viral load and normal ALT after initial entecavir treatment. METHODS: This is a 2-year prospective trial of 50 patients treated on entecavir 0.5 mg daily for over 6 months, and had …-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatologyen_US
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleSwitching to lamivudine in entecavir-treated patients with undetectable HBV DNA - final results at 96 weeksen_US
dc.typeConference_Paperen_US
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0270-9139&volume=52&issue=Suppl. S1&spage=549A, abstract no. 462&epage=&date=2010&atitle=Switching+to+lamivudine+in+entecavir-treated+patients+with+undetectable+HBV+DNA+-++final+results+at+96+weeks-
dc.identifier.emailFung, J: jfung@hkucc.hku.hken_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailWong, D: danywong@hku.hken_US
dc.identifier.emailYuen, MF: mfyuen@hku.hken_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.authorityWong, D=rp00492en_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/hep.23990-
dc.identifier.hkuros190375en_US
dc.identifier.volume52en_US
dc.identifier.issuesuppl. S1en_US
dc.identifier.spage549Aen_US
dc.identifier.epage549Aen_US
dc.description.otherThe 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462-
dc.identifier.issnl0270-9139-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats